Meta Biomed

KOSDAQ-059210
KOSDAQ NYSE
Dental Equipment and Supplies
Global Rank
#23488
Country Rank
#1005
Market Cap
113.63 M
Price
4.17
Change (%)
6.09%
Volume
1.45 M

Meta Biomed's latest marketcap:

113.63 M

As of 06/08/2025, Meta Biomed's market capitalization has reached $113.63 M. According to our data, Meta Biomed is the 23488th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 113.63 M
Revenue (ttm) 72.44 M
Net Income (ttm) 16.37 M
Shares Out 27.26 M
EPS (ttm) 0.47
Forward PE 0.00
Ex-Dividend Date 12/27/2024
Earnings Date 05/14/2025
Market Cap Chart
Data Updated: 06/08/2025

Meta Biomed's yearly market capitalization.

Meta Biomed has seen its market value grow from ₩64.35 B to ₩155.66 B since 2020, representing a total increase of 141.88% and an annual compound growth rate (CAGR) of 22.02%.
Date Market Cap Change (%)
06/08/2025 ₩155.66 B 83.44%
12/30/2024 ₩84.85 B -14.91%
12/28/2023 ₩99.72 B 88.74%
12/29/2022 ₩52.83 B -20.17%
12/30/2021 ₩66.18 B 2.85%
12/30/2020 ₩64.35 B

Company Profile

About Meta Biomed Co., Ltd.

Meta Biomed Co., Ltd. is a leading company specializing in the research, development, and production of dental and surgical materials. Headquartered in Cheongju-si, South Korea, the company operates globally, serving markets in Asia, Europe, the United States, and Africa.

Core Product Offerings

  • Dental Products: Endodontics, dental equipment, restorative materials, and bone graft materials.
  • Suture Products: Multifilament and monofilament sutures, functional and orthopedic suture materials.
  • Biomaterials: Polymer, multifilament yarn, 3D printing filaments, and bioceramic powder.
  • Auxiliary Materials: Aluminum pouches, needles, glue, glove boxes, barbing machines, and diameter testers.
  • Medical Devices: Used in general surgery, orthopedics, neurosurgery, and OB-GYN.
  • Cosmetic Medical Products: HA fillers, PDO fillers, skin boosters, and threads.

Company Background

Founded in 1990, the company was originally known as Metadental Co., Ltd. before rebranding to Meta Biomed Co., Ltd. in 2001. Since its inception, the company has been committed to innovation and quality in the medical and dental fields.

Frequently Asked Questions

  • What is Meta Biomed's (KOSDAQ-059210) current market cap?
    As of 06/08/2025, Meta Biomed (including the parent company, if applicable) has an estimated market capitalization of $113.63 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Meta Biomed global market capitalization ranking is approximately 23488 as of 06/08/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking
Community

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.